ScreenerHero

PHIO Phio Pharmaceuticals Corp.

NAS · US · Healthcare · Biotechnology · phiopharma.com
0.9944USD+0.34%Mkt Cap: 11.55M $P/E: —

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INSM
Insmed Incorporated
$22.98BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap11.55M USD
Enterprise Value-1.44M USD
Revenue (TTM)—
Gross Profit-8.53M USD
Net Income (TTM)-8.70M USD
Revenue/Share—
Last Price0.9944 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.63
PEG—
EV/EBITDA0.11
EV/Revenue—
P/S—
P/B0.92
EPS (TTM)-1.29
EPS (Forward)-0.61
52W Range
0.81305% of range4.190
52W High4.190 USD
52W Low0.8130 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-43.17%
ROA-40.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.98M USD
CapEx (TTM)12.00K USD
FCF Margin—
FCF Yield-66.86%
Net Debt-13.00M USD
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity—
Current Ratio8.39
Quick Ratio7.62
Book Value/Sh1.08 USD
Cash/Share1.12 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 15, 2020
Splits
Last Split1:9
Split DateJul 5, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.00 USD
Upside (mean)+1307.9%
Target Range14.00 USD – 14.00 USD
# Analysts1
Ownership
Shares Out.11.62M
Float11.26M
Insiders8.01%
Institutions10.21%
Short Interest
Short Ratio0.8d
Short % Float1.30%
Short % Out.1.29%
Shares Short149.89K
Short (prev mo.)319.75K
Technical
SMA 501.061 (-6.3%)
SMA 2001.107 (-10.1%)
Beta0.84
S&P 52W Chg16.45%
Avg Vol (30d)145.63K
Avg Vol (10d)118.19K
Technical Indicators
RSI (14)41.3
MACD-0.0200
MACD Signal-0.0169
MACD Hist.-0.0031
BB Upper1.081 USD
BB Middle1.023 USD
BB Lower0.9649 USD
BB Width11.36%
ATR (14)0.0516 USD
Vol Ratio (20d)1.03x